Gan & Lee Pharmaceuticals Deal History & Licensing Activity
Gan & Lee Pharmaceuticals is a biotech headquartered in US. Over the past three years, Gan & Lee Pharmaceuticals has been involved in 2 licensing and acquisition transactions, with a primary focus on Peptides (4 deals). The company currently has 29 active clinical trials, primarily in Metabolic.
Deals (12mo)
2
Active Trials
29
Top Modality
Peptides
Focus Area
Metabolic
Gan & Lee Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Gan & Lee Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Bofanglutide | Menarini Group | Peptides | Phase 2 | license | Sep 3, 2026 |
| Bofanglutide Injection | JW Pharmaceutical | Peptides | Phase 3 | license | Apr 9, 2026 |
Gan & Lee Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Gan & Lee Pharmaceuticals is most active based on deal history and clinical trial data.
Gan & Lee Pharmaceuticals Clinical Pipeline
Gan & Lee Pharmaceuticals has 29 active clinical trials across 3 development phases.
14
Phase 1
2
Phase 2
13
Phase 3
See How Your Asset Matches Gan & Lee Pharmaceuticals's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Gan & Lee Pharmaceuticals Licensing & Deal Activity
Gan & Lee Pharmaceuticals is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Gan & Lee Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Gan & Lee Pharmaceuticals include Metabolic (28 deals and trials), Solid Tumors (1 deal and trial), and Respiratory (1 deal and trial). In terms of modality, Gan & Lee Pharmaceuticals has shown particular interest in peptides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Gan & Lee Pharmaceuticals and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Gan & Lee Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.